Latest Memorial Sloan–Kettering Cancer Center Stories
The Cancer Research Institute (CRI) declares June “Cancer Immunotherapy Awareness Month” to increase awareness of cancer immunotherapy, a new class of cancer treatment that mobilizes the immune system to fight the disease and represents the most immediate hope for curing patients with any type of cancer. The month will feature educational webinars offered free to the public from top experts in cancer immunotherapy, and a Wear White for a Cure Day on June 7. New York, NY (PRWEB) May 08,...
XF Technology Brings New Perspective to Cancer Metabolism BILLERICA, Mass., April 4, 2013 /PRNewswire/ -- Seahorse Bioscience, the world leader in instruments and assay kits for measuring cell metabolism announces travel award recipients who will present data generated using XF technology at the American Association of Cancer Research (AACR) Annual Meeting, in Washington, DC, April 6-10, 2013. Kate M. Bailey, Ph.D., candidate in the lab of Robert J. Gillies, Ph.D., at the H. Lee...
Memorial Sloan-Kettering Cancer Center's national fundraising event has raised more than $31 million for rare cancer research since 2007 with founding partner, Equinox NEW YORK, March 11, 2013 /PRNewswire/ -- More than 12,000 cyclers gathered in ten cities across the country in February and early March to raise more than $13.8 million to support rare cancer research at Memorial Sloan-Kettering Cancer Center. The events took place at Equinox clubs in New York City; Los Angeles; San...
NEW YORK, Feb. 19, 2013 /PRNewswire/ -- In July 2013, Walk the Walk will bring The MoonWalk marathon from the United Kingdom to America for the first time to raise awareness and funds for breast cancer causes. At 10 p.m., on July 20, 2013, thousands of women and men will Power Walk through the city wearing brightly decorated bras to inspire and encourage others to get fit, have fun, and raise money for breast cancer charities in New York. Presented by Empire BlueCross BlueShield,...
NEW YORK, Feb. 8, 2013 /PRNewswire/ -- IBM (NYSE: IBM), WellPoint, Inc. (NYSE: WLP) and Memorial Sloan-Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence based medicine. (Photo: http://photos.prnewswire.com/prnh/20130208/NY57025 )(Logo:...
BEVERLY HILLS, Calif., Jan. 22, 2013 /PRNewswire/ -- Dr. Andrew Ordon, Board Certified Plastic Surgeon and co-host of the daytime talk show, The Doctors, and his surgical group at the Rox Center in Beverly Hills are announcing the founding of the Rox Cancer Center. This private medical corporation is focused around Dr. Travis Kidner who is a formally trained surgical oncologist and Board Certified General Surgeon. "Dr. Kidner brings expertise and experience from Memorial Sloan...
NEW YORK, Oct. 24, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., (API), a private biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced that the poster summarizing the results for Phase I study of Actimab-A, its antibody directed alpha emitter drug candidate, has won a first place poster presentation award at the 8th Annual Hematologic Malignancies 2012 Conference held in Houston, TX, from October 10-14. The award was presented to...
NEW YORK, Oct. 10, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., (API), a privately held biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced the presentation of a scientific poster summarizing the results for a Phase I study of Actimab-A, its antibody directed alpha emitter drug candidate for the front line treatment of acute myeloid leukemia in older patients. Actimab-A was evaluated in a Phase I dose escalating trial at...
NEW YORK, Sept. 19, 2012 /PRNewswire/ -- Online registration is now open for Cycle for Survival, Memorial Sloan-Kettering Cancer Center's national indoor team cycling event that has raised more than $17 million for rare cancer research, funding more than 50 clinical trials and research studies since 2007. Cycle 2013 is expected to be the largest event yet, spanning 10 locations in eight states and bringing together more than 13,000 cyclers nationwide. The 2013 event schedule is as...
NEWARK, N.J., July 19, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A(TM) in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City....
